Who Makes Stem Cell Conditioned Media, and Where? Dr. Moriwaki Explains the Framework of Notified Cell-Processed Product Manufacturing Facilities and Lot Traceability2026.07.27

As scalp treatment using stem cell conditioned media becomes more widespread, it is not uncommon for the most basic question — “Who actually makes this conditioned media, and at which facility?” — to remain unexplained to the patient until the contract is signed. Conditioned media is not an approved pharmaceutical under the Pharmaceuticals and Medical Devices Act; it is a biologically derived preparation handled under a separate framework, the Act on the Safety of Regenerative Medicine. For this reason, verifying the manufacturing background matters just as much as discussions about efficacy or side effects. In this article, supervising physician Dr. Shin Moriwaki explains — from a practical standpoint — the regulatory position of cell-processed product manufacturing and how patients can verify lot traceability using publicly available information.

Key Points of This Article

・Conditioned media is not an approved pharmaceutical; it is a biologically derived preparation manufactured at facilities notified under the cell-processed product manufacturing framework of the Act on the Safety of Regenerative Medicine.

・”Who makes it and where” is information that should be disclosed to any patient who requests it, at the level of publicly available data.

・Only when three items — lot number, Certificate of Analysis (CoA), and manufacturing facility name — are aligned is lot traceability truly ensured.

・If a clinic hesitates to disclose manufacturing information, there is a risk that the raw materials or processes cannot be independently verified.

・Whether a facility is a notified cell-processed product manufacturing site can be cross-checked against information published by Japan’s Ministry of Health, Labour and Welfare.

Why “Who Makes It” Matters

Conditioned media is not the stem cells themselves but is derived from the “culture supernatant” — a mixture of growth factors, cytokines, and exosomes secreted into the culture medium as stem cells are grown. Even though no living cells are contained, every step of the manufacturing process — donor background of the source cells, medium composition, level of aseptic technique, freezing and transport controls — shapes the character of the final product. Because what is injected into the scalp is an invisible liquid, a system that lets patients verify the upstream process functions as a safety net.

The Same Product Name Can Contain Very Different Contents

Differences such as umbilical-cord-derived versus adipose-derived, or serum-free versus serum-containing medium, directly affect the type and quantity of growth factors present. Add donor age, passage number, and harvest timing, and even the same product name can vary in composition from lot to lot. Understanding this makes clear why the ability to trace “who made this conditioned media and where” carries concrete meaning for patient safety and treatment design.

The Framework of Cell-Processed Product Manufacturing

Under the Act on the Safety of Regenerative Medicine, notification categories of Class I, II, and III are set for the act of processing cells for clinical application, according to risk level. Treatments that administer the cells themselves fall under this classification, while conditioned media is positioned as a secretion arising from the processing — not as “the cell-processed product itself.” Nevertheless, the facility that manufactures conditioned media is required to follow hygiene and quality controls in line with the cell-processed product manufacturing framework. “Because no cells are in the medium, the system does not apply” is not an accurate explanation: as long as a process handles source cells, a certain notification responsibility falls on the manufacturing facility.

Manufacturing Facility and Clinic Are Often Separate Entities

Many clinics do not manufacture conditioned media in-house; they purchase products from external notified manufacturing facilities and administer them to patients. Recognizing this structure clarifies that “the attending physician’s technique” and “the quality of the conditioned media itself” need to be evaluated on different layers. Even under the same clinic name, the two responsibilities lie in different places.

How Patients Can Verify Lot Traceability

The Three-Piece Set: Lot Number, CoA, Manufacturing Facility Name

Any conditioned media derived from trustworthy cell-processed product manufacturing carries a lot number. Starting from the lot number, a Certificate of Analysis (CoA) lets you confirm results such as sterility testing, mycoplasma testing, and endotoxin testing, and you can further cross-check “which facility made it.” Without these three items aligned, patients cannot retrospectively verify what was injected into them.

Cross-Checking the Facility Name in Public Records

The list of regenerative-medicine-providing institutions and the list of notified cell-processed product manufacturing facilities, published by Japan’s Ministry of Health, Labour and Welfare, are available to the public. Simply confirming that the facility name disclosed by a clinic appears on those lists already verifies a minimum level of traceability. From this list of related columns on hair regenerative medicine, you can also read related explanations of safety testing and how to read a CoA.

Questions Worth Asking the Clinic

Before signing a treatment contract, it is reassuring to confirm the following with the attending physician: the cell source of the conditioned media, the manufacturing facility name, the lot number, whether a CoA is issued, the freeze/thaw/transport cold chain, and the expiration date. For products manufactured at a notified facility, these are normally disclosable. If the clinic hesitates to disclose or cannot answer immediately, it becomes reasonable grounds to doubt how well that facility grasps its own product quality. For the position of regenerative medicine within dermatology, please also consult the guidelines of the Japanese Dermatological Association when making a careful choice.

Dr. Moriwaki’s Perspective: Response to Information Disclosure Is an Index of Trust

From the experience of seeing many conditioned media products in clinical practice, facilities that can properly explain the background of cell-processed product manufacturing also tend to be careful in the design of dosing protocols and response to side effects. Conversely, facilities that blur their manufacturing information behind words like “proprietary process” or “special route” often reveal their essence when patients ask one step deeper. Before entering discussions of efficacy or price, first confirm: “Who makes this conditioned media, and where?” This small extra step is the first line of self-defense in hair regenerative medicine. Rather than absolute promises of results or overly optimistic explanations, the ability to calmly disclose the mundane manufacturing details is, in the long run, a far more trustworthy indicator.

Frequently Asked Questions

Q. Should I avoid conditioned media labeled as “proprietary process”?

The expression “proprietary process” itself is not illegal. In reality, however, there are many cases where the manufacturing facility name, lot number, and CoA cannot be disclosed. Confirm that the product is made within the cell-processed product manufacturing framework, and use “whether the necessary documents can be produced” as your standard of judgment.

Q. The clinic will not tell me the lot number. How should I respond?

The lot number of the administered product is information that should normally be disclosed upon patient request. Because preparations from notified facilities always carry a number, refusal to disclose itself becomes a data point for your decision.

Q. Even with a CoA, the technical terms are hard to read. What should I look at?

First confirm that the “Pass” judgments for sterility testing, mycoplasma testing, and endotoxin testing appear side by side. For interpretation of finer numeric values, ask the attending physician; the content should be answerable as part of quality control.

Q. Does conditioned media imported from overseas fall under Japan’s system as well?

When used clinically in Japan, the domestic framework of the Act on the Safety of Regenerative Medicine applies in principle. Even when raw materials of overseas origin are used, please always confirm that a notified domestic facility is involved.

Q. Does the disclosure of manufacturing information mean that efficacy is also guaranteed?

Disclosure ensures “transparency of quality and process”; it does not promise the outcome of an individual patient. A clear manufacturing background is a prerequisite, and only when it is combined with injection technique, treatment design, and the patient’s own hair-cycle conditions can clinical results be expected.

──────────────

【Supervising Physician】Shin Moriwaki, MD

Member, Japan Society of Aesthetic Surgery (JSAS) / American Academy of Aesthetic Medicine

ECFMG Certificate

──────────────

📍AVAN TOKYO Ginza Hair Regenerative Medicine

English / 中文 / Tiếng Việt available

Inquiries welcomed via DM / LINE / Website / Phone.